Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase Ib Study on the Safety, Tolerability, and Efficacy of BT02 in Treating Patients With Advanced Lung Cancer

NCT07110363 is registered in ClinicalTrials.gov with Biotroy Therapeutics as lead sponsor.

NCT NCT07110363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07110363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase Ib Study on the Safety, Tolerability, and Efficacy of BT02 in Treating Patients With Advanced Lung Cancer
Lead sponsor
Biotroy Therapeutics
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 31, 2025
Completion date
May 31, 2027
Enrollment
58 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced lung cancer, advanced malignant solid tumor, non-small cell lung cancer, small cell lung cancer